Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Research Notes

Open Access

Autoantibodies directed to centromere protein F in a patient with BRCA1 gene mutation

  • Fiona Moghaddas1Email author,
  • Fredrick Joshua2,
  • Roberta Taylor1,
  • Marvin J. Fritzler3 and
  • Ban Hock Toh1, 4
BMC Research Notes20169:84

https://doi.org/10.1186/s13104-016-1908-7

Received: 30 March 2015

Accepted: 3 February 2016

Published: 11 February 2016

Abstract

Background

Autoantibodies directed to centromere protein F were first reported in 1993 and their association with malignancy has been well documented.

Case

We present the case of a 48-year-old Caucasian female with a BRCA1 gene mutation associated with bilateral breast cancer. Antinuclear autoantibody immunofluorescence performed for workup of possible inflammatory arthropathy showed a high titre cell cycle related nuclear speckled pattern, with subsequent confirmation by addressable laser bead immunoassay of the target antigen as an immunodominant epitope at the C-terminus of centromere protein F.

Conclusion

Here we review the current literature on centromere protein F, its association with breast cancer and present the first case of this antibody being identified in a person with a BRCA1 gene mutation.

Keywords

CENP-FAntinuclear antibodyMalignancyBRCA1ALBIA

Background

Centromere protein-F (CENP-F), also known at mitosin, is a ~400 kDa nuclear protein encoded by gene 1q32–41 that associates with the centromere kinetochore complex [1, 2]. It functions in a cell cycle manner, present as a nuclear matrix protein during interphase then redistributing during early G2 of the cell cycle [14]. Since its discovery in 1993, a number of its functions have been elucidated, including involvement in centromere maturation, regulation of metaphase checkpoint and ensuring appropriate orientation of chromosomes [49]. Furthermore, it is involved in the attenuation of histone methylation and negative regulation of activating transcription factor-4 (ATF4), a transcription factor important for stress proliferation and differentiation of cells [1, 10].

The expression of CENP-F in malignancies has been investigated over the past decade, with increased immunohistochemical expression of CENP-F reported in breast, lung, ovarian and cervical cancer, non-Hodgkin lymphoma as well as squamous cell carcinoma of the oesophagus, oral mucosa and gingiva [7, 11]. Elevated expression of CENP-F has prognostic implications, correlating with clinical and pathological parameters of poor prognosis in primary breast cancer including higher standardised uptake values on positron emission tomography (PET) scan, shorter disease free survival times and higher recurrence rates [12, 13]. O’Brien et al. investigated the role of CENP-F in primary breast cancer with tissue microarrays in two cohorts and noted that CENP-F mRNA overexpression (set at >10 % based on previous studies) was significantly associated with increased tumour size, higher tumour grade and oestrogen receptor (ER) negativity [12].

Antibodies directed towards antigens expressed in tumour cells including CENP-F have been well described. Indirect immunofluorescence (IIF) of CENP-F autoantibody positive serum using Hep-2 cell line shows a nuclear speckled pattern with cell cycle dependent fluorescence and negative chromatin mass in mitosis [14]. Although present in less than 1 % of patients with malignancy, anti-CENP-F antibodies have a positive predictive value of approximately 50 % for cancer [1416]. Furthermore, there is evidence to suggest that the appearance of these antibodies may be seen during progression from benign to malignant processes, as was demonstrated in two patients peri transition from chronic hepatitis to hepatocellular carcinoma as well as in oral leukoplakia, a premalignant lesion of the oral mucosa [1719].

Previously, anti-CENP-F antibodies have been detected using radioimmunoassay, immunoblotting with native recombinant antigens or enzyme linked immunosorbent assay [16]. A more recent development has employed an addressable laser bead immunoassay (ALBIA) based on the two principal immunogenic epitopes of CENP-F, peptides F1 and F4 [14, 20, 21]. Interestingly, half of patients who tested positive for CENP-F using this method did not have the corresponding typical IIF pattern, suggesting that IIF may be an insensitive screening method for this autoantibody, and that the incidence in patients with malignancy may indeed be more than 1 %.

The potential therapeutic benefit of detecting increased expression of CENP-F, or autoantibodies directed towards it, has been studied with the use medications such as zoledronic acid that target farnesyl diphosphate synthase [22]. CENP-F is a farnesylated protein and inhibition of farnesylation leads to loss of CENP-F from the kinetochore and subsequent inactivation [22]. Farnesyl transferase inhibitors (FTIs) are a novel class of chemotherapeutic agents showing promise in the treatment of cancer [23]. Although thought to act mainly by its downstream effects on Ras, the actions of FTIs are not Ras-specific and it is possible that the lack of farnesylation of other proteins, including CENP-F, may have a role in their success [12, 2326].

To date, neither the over expression of CENP-F nor the detection of autoantibodies directed towards it have been described in a BRCA1 mutation positive population. BRCA1, a tumour suppressor gene located on chromosome 17, is mutated at high frequency in hereditary breast and ovarian cancers. The role of CENP-F in pathogenesis of disease in this population, and the theoretical benefit of FTIs, has not yet been explored.

Case report

A 48-year-old Caucasian female was referred to a rheumatologist experiencing fatigue and widespread joint pain, worse in the morning and improving with activity, associated with new onset psoriasis. The results from a number of investigations performed 3 months prior to review include C-reactive protein 16 (n < 5 mg/L), erythrocyte sedimentation rate 57 (n < 20 mm/h), and a negative rheumatoid factor and HLA-B27. An antinuclear antibody (ANA) performed at this time was reported as positive at a titre of 1:1280 with a speckled pattern, but antibodies to extractable nuclear antigens (ENA) and ds-DNA were negative.

The ANA was repeated by IIF on the HEp-2000 Fluorescent ANA-Ro60 Test System according to the manufacturer’s directions (Immuno Concepts, Sacramento, CA). The sample was screened at a dilution of 1:160 and sequentially diluted at titres 1:320, 1:640 and 1:1280 with the result recorded as the highest dilution ANA pattern remained discernible. The repeat ANA showed a nuclear speckled-II (NSII) pattern [27] at a titre of 1:1280 (Fig. 1). The NSpII pattern is a cell cycle dependent pattern suggestive of CENP-F autoantibodies, typically characterised by strong centromere staining in prometaphase and metaphase, variable nuclear staining in interphase and weak staining in anaphase. Approximately 60 % of sera demonstrating this pattern also have staining of the midbody during telophase (Fritzler unpublished data). As there were no commercially available assays identifying this specificity, the sample was sent to the Mitogen Advanced Diagnostics Laboratory at the University of Calgary where an ALBIA was developed for this purpose using protocols as previously described [28]. This process involved covalent coupling CENP-F peptides F1 and F4 to separate dye laden addressable microbeads and pipetting both into a single microtiter well, with the subsequent addition of both serum and fluorochrome-coupled secondary antibody. The sample was then processed by a Luminex 200 analyser (Luminex Corp., Austin, TX). The two lasers in the instrument and flow cytometric principles allowed determination of both specificity and quantification of autoantibody, with results expressed as mean fluorescence units (MFU) of the fluorochrome-coupled secondary antibody [28]. Antibodies to both epitopes were detected in the patient’s serum, with a low positive reading for p-F1 and a high positive for p-F4.
Fig. 1

Cell cycle dependent pattern characterised by strong centromere staining in prophase (A) and prometaphase (A, B), variable nuclear staining in interphase (C), weak staining in metaphase (D) and staining of midbody during anaphase and early telophase (E). Hep-2000 Fluorecent ANA-Ro Test System (Immuno Concepts), 1:160, 40× magnification

Given the association of this autoantibody specificity with malignancy, further history was sought from the referring clinician. At age 45, the patient was diagnosed with stage III left sided breast cancer and underwent mastectomy, axillary clearance and combined adjuvant chemotherapy and radiotherapy. Her post-treatment course was complicated by melanoma in the field of radiation. She underwent genetic testing for risk stratification and was noted to be BRCA1 positive. Approximately 1 year after the initial diagnosis she underwent a prophylactic bilateral salpingo-oophorectomy, with two foci of severe dysplasia seen in the right fallopian tube. Six months later, she was noted to have lymphadenopathy in the contralateral axillae that was biopsied and positive for adenocarcinoma, and subsequently had a right mastectomy and axillary clearance.

Discussion

There have been no reports of antibodies to CENP-F expressed in patients who are BRCA1 gene mutation positive. Literature on the association of CENP-F immunohistochemical staining in breast cancer of patients with BRCA1 mutation is also lacking. There are a number of potential reasons for this, including the questionable value of detecting this marker of high risk in a population that will already undergo rigorous monitoring for recurrence post diagnosis. Furthermore, the genetic heterogeneity in breast cancer may lead to the presumption that the co-existence of these autoantibodies may indeed be coincidental, and antibodies to multiple autoantigens may be detected if tested. In an unselected breast cancer population, Fritzler et al. documented 7/190 (3.7 %) of breast cancer patients testing positive for CENP-F autoantibodies [14]. The rate of positivity in the BRCA1 population is unclear, and cohort studies may help clarify this. The implication of this information, however, is less certain.

There is little information on the use of these autoantibodies as a marker of disease remission or recurrence. One report identified a single patient with breast cancer and undifferentiated connective tissue disease and tracked the mean fluorescence units (MFU) of autoantibodies targeting both p-F1 and p-F4 over time [14]. The relationship between autoantibody levels, epitope specificity and the clinical picture was not clear. As these autoantibodies are unlikely to be singularly causal, we cannot necessarily expect to find such a linear association. Whether there is utility in monitoring antibodies to CENP-F in patients who have tested positive remains to be determined. There have been no reports of patients having CENP-F positivity reverting to negative, and there is insufficient data on the semi quantitative and quantitative measures in individual patients over time. It is difficult to determine the future risk of malignancy in our patient, and although the positive predictive value of malignancy in those testing positive is 50 %, there is no literature on whether this risk changes after detection and treatment of an initial malignancy.

As mentioned above, there are theoretical benefits of FTI in patients with malignancies who express autoantibodies to CENP-F. This is difficult to study directly due to small numbers of patients with CENP-F antibodies and FTIs currently being in trial, but it does raise the prospect of this class of agent being effective in this population. Our patient has already been exposed to multiple chemotherapeutic agents and it is foreseeable that she may require treatment for further malignancies. This may prove to be a useful option in the future.

Conclusion

This case highlights the association of CENP-F with malignancy, as well as deficiencies in our current knowledge of autoantibodies targeting this antigen. The incidence of these autoantibodies in patients with a BRCA1 mutation is unknown. Further research into the prevalence in the BRCA1 population may provide useful information for patient care as the target antigen is implicated in the mechanism of action of chemotherapeutic agents.

Consent

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Abbreviations

ALBIA: 

addressable laser bead immunoassay

ANA: 

antinuclear antibody

ATF4: 

activating transcription factor-4

BRCA1: 

breast cancer 1

CENP-F: 

centromere protein F

ENA: 

extractable nuclear antigens

ER: 

oestrogen receptor

FTI: 

farnesyltransferase inhibitors

IIF: 

indirect immunofluorescence

MFU: 

mean fluorescence units

NSII: 

nuclear speckled-II pattern

PET: 

positron emission tomography

Declarations

Authors’ contributions

FM reviewed the antinuclear antibody indirect immunofluorescence, carried out literature review and drafted case report. FJ provided clinical information on the patient. RT performed antinuclear antibody indirect immunofluorescence. MJF performed ALBIA for CENP-F confirmation and provided expertise on interpretation of results. BHT supervised FM and assisted with manuscript preparation and editing. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank the patient for consenting to be involved in this case report.

Competing interests

MF is the director of Mitogen Advanced Diagnostics Laboratory.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Australian Clinical Laboratories
(2)
Department of Rheumatology, Prince of Wales Hospital
(3)
Department of Medicine, University of Calgary
(4)
Department of Medicine, Nursing and Health Sciences, Monash University

References

  1. Du J, Li Y, Zhu X. Involvement of CENP-F in histone methylation. Acta Biochim Biophys Sin. 2010;42(3):173–6 (Shanghai).View ArticlePubMedGoogle Scholar
  2. Rattner JB, et al. CENP-F is a.ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Motil Cytoskeleton. 1993;26(3):214–26.View ArticlePubMedGoogle Scholar
  3. Landberg G, et al. Nuclear autoantigen p330d/CENP-F: a marker for cell proliferation in human malignancies. Cytometry. 1996;25(1):90–8.View ArticlePubMedGoogle Scholar
  4. Ma L, Zhao X, Zhu X. Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. J Biomed Sci. 2006;13(2):205–13.View ArticlePubMedGoogle Scholar
  5. Bomont P, et al. Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F. EMBO J. 2005;24(22):3927–39.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Du J, et al. Involvement of Cenp-F in interphase chromatin organization possibly through association with DNA-dependent protein kinase. Acta Biochim Biophys Sin. 2010;42(12):839–46 (Shanghai).View ArticlePubMedGoogle Scholar
  7. Esguerra RL, et al. Immunohistochemical analysis of centromere protein F expression in buccal and gingival squamous cell carcinoma. Pathol Int. 2004;54(2):82–9.View ArticlePubMedGoogle Scholar
  8. Feng J, Huang H, Yen TJ. CENP-F is a novel microtubule-binding protein that is essential for kinetochore attachments and affects the duration of the mitotic checkpoint delay. Chromosoma. 2006;115(4):320–9.View ArticlePubMedGoogle Scholar
  9. Varis A, Salmela AL, Kallio MJ. Cenp-F (mitosin) is more than a mitotic marker. Chromosoma. 2006;115(4):288–95.View ArticlePubMedGoogle Scholar
  10. Zhou X, et al. Mitosin/CENP-F as a negative regulator of activating transcription factor-4. J Biol Chem. 2005;280(14):13973–7.View ArticlePubMedGoogle Scholar
  11. Mi YJ, et al. Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma. Dis Esophagus. 2013;26(6):636–43.View ArticlePubMedGoogle Scholar
  12. O’Brien SL, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer. 2007;120(7):1434–43.View ArticlePubMedGoogle Scholar
  13. Ueda S, et al. Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer. 2008;8:384.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Fritzler MJ, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev. 2011;10(4):194–200.View ArticlePubMedGoogle Scholar
  15. Abu-Shakra M, et al. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis. 2001;60(5):433–41.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Welner S, et al. Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay. Mol Cancer. 2013;12(1):95.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Covini G, et al. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol. 1997;26(6):1255–65.View ArticlePubMedGoogle Scholar
  18. Liu SC, et al. Markers of cell proliferation in normal epithelia and dysplastic leukoplakias of the oral cavity. Cancer Epidemiol Biomarkers Prev. 1998;7(7):597–603.PubMedGoogle Scholar
  19. Zhang JY, et al. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol. 2001;125(1):3–9.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Fritzler MJ. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus. 2006;15(7):422–7.View ArticlePubMedGoogle Scholar
  21. Rattner JB, et al. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med. 1997;20(5):308–19.PubMedGoogle Scholar
  22. Brown HK, et al. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med. 2011;15(3):501–13.PubMed CentralView ArticlePubMedGoogle Scholar
  23. de Bono JS, Tolcher AW, Rowinsky EK. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. Semin Oncol. 2003;30(5 Suppl 16):79–92.PubMedGoogle Scholar
  24. Ashar HR, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000;275(39):30451–7.View ArticlePubMedGoogle Scholar
  25. Hussein D, Taylor SS. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci. 2002;115(Pt 17):3403–14.PubMedGoogle Scholar
  26. Schafer-Hales K, et al. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther. 2007;6(4):1317–28.View ArticlePubMedGoogle Scholar
  27. Fritzler MJ, Valencia DW, McCarty GA. Speckled pattern antinuclear antibodies resembling anticentromere antibodies. Arthritis Rheum. 1984;27(1):92–6.View ArticlePubMedGoogle Scholar
  28. Eystathioy T, et al. Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. J Mol Med. 2003;81(12):811–8 (Berl).View ArticlePubMedGoogle Scholar

Copyright

© Moghaddas et al. 2016

Advertisement